Innovations in drug formulation now allow many parenteral therapies to be delivered via subcutaneous injection. These developments have mainly been driven by the rise of biologics and biosimilars, but they often result in larger dose volumes and less frequent dosing as well.
Although beneficial for patients and healthcare systems, these trends introduce new complexities for manufacturers.
Tim Holden, Head of Business Development and Marketing at Owen Mumford Pharmaceutical Services, reports.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.